X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DR. DATSONS LABS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DR. DATSONS LABS GLENMARK PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 19.0 -10.9 - View Chart
P/BV x 3.4 0.2 2,074.7% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
GLENMARK PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs930126 740.4%   
Low Rs51731 1,674.4%   
Sales per share (Unadj.) Rs322.6133.0 242.6%  
Earnings per share (Unadj.) Rs28.50.2 18,790.8%  
Cash flow per share (Unadj.) Rs39.26.6 593.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0128.8 142.1%  
Shares outstanding (eoy) m282.1731.66 891.3%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x2.20.6 381.3%   
Avg P/E ratio x25.4516.1 4.9%  
P/CF ratio (eoy) x18.511.8 155.9%  
Price / Book Value ratio x4.00.6 650.9%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2062,477 8,242.8%   
No. of employees `00013.7NA-   
Total wages/salary Rs m18,71856 33,425.7%   
Avg. sales/employee Rs Th6,636.8NM-  
Avg. wages/employee Rs Th1,364.7NM-  
Avg. net profit/employee Rs Th586.1NM-  
INCOME DATA
Net Sales Rs m91,0314,211 2,162.0%  
Other income Rs m91479 1,161.4%   
Total revenues Rs m91,9454,289 2,143.6%   
Gross profit Rs m16,154569 2,841.0%  
Depreciation Rs m3,019204 1,476.9%   
Interest Rs m2,856430 663.8%   
Profit before tax Rs m11,19313 88,136.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1556 51,714.8%   
Profit after tax Rs m8,0395 167,472.9%  
Gross profit margin %17.713.5 131.4%  
Effective tax rate %28.248.0 58.7%   
Net profit margin %8.80.1 7,746.2%  
BALANCE SHEET DATA
Current assets Rs m69,8876,852 1,020.0%   
Current liabilities Rs m32,8796,711 490.0%   
Net working cap to sales %40.73.3 1,214.0%  
Current ratio x2.11.0 208.2%  
Inventory Days Days81161 50.6%  
Debtors Days Days93318 29.4%  
Net fixed assets Rs m28,8923,673 786.6%   
Share capital Rs m282317 89.1%   
"Free" reserves Rs m51,3533,761 1,365.4%   
Net worth Rs m51,6354,078 1,266.3%   
Long term debt Rs m41,4181,671 2,478.9%   
Total assets Rs m125,95412,633 997.1%  
Interest coverage x4.91.0 477.9%   
Debt to equity ratio x0.80.4 195.8%  
Sales to assets ratio x0.70.3 216.8%   
Return on assets %8.63.4 251.2%  
Return on equity %15.60.1 13,225.0%  
Return on capital %15.17.7 196.8%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m36,317964 3,767.3%   
Fx outflow Rs m9,720607 1,601.0%   
Net fx Rs m26,598357 7,452.4%   
CASH FLOW
From Operations Rs m16,4811,345 1,225.5%  
From Investments Rs m-10,133-2,256 449.3%  
From Financial Activity Rs m-4,685-1,200 390.5%  
Net Cashflow Rs m1,770-2,111 -83.9%  

Share Holding

Indian Promoters % 48.3 4.5 1,066.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 1.4 2,548.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 94.1 11.2%  
Shareholders   56,727 20,807 272.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUVEN LIFESCIENCES  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 222 Points Lower; Energy and Telecom Stocks Witness Selling(Closing)

Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Mar 22, 2019 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS